Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
Discontinued
Reference number: GID-TA10779
Following on from information provided to NICE by the company in September 2022, the appraisal of Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889] was suspended from NICE’s work programme. The company will no longer be pursuing a Marketing Authorisation Application in the UK in this indication at this time. Therefore, NICE has decided to discontinue this topic.